{"title":"Parenteral nutrition and bioelectrical impedance analysis estimated fat-free mass in adult patients with chronic intestinal failure: A descriptive cohort study","authors":"Trevor Tabone MD","doi":"10.1002/jpen.2752","DOIUrl":"10.1002/jpen.2752","url":null,"abstract":"","PeriodicalId":16668,"journal":{"name":"Journal of Parenteral and Enteral Nutrition","volume":"49 5","pages":""},"PeriodicalIF":4.1,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Association between a 6-h feeding protocol and postprocedure hospital length of stay following percutaneous endoscopic gastrostomy in hospitalized adults: A before-and-after cohort study","authors":"Trevor Tabone MD","doi":"10.1002/jpen.2751","DOIUrl":"10.1002/jpen.2751","url":null,"abstract":"","PeriodicalId":16668,"journal":{"name":"Journal of Parenteral and Enteral Nutrition","volume":"49 4","pages":"402-403"},"PeriodicalIF":4.1,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p><b>Sunday, March 23, 2025</b></p><p><b>SU30 Parenteral Nutrition Therapy</b></p><p><b>SU31 Enteral Nutrition Therapy</b></p><p><b>SU32 Malnutrition and Nutrition Assessment</b></p><p><b>SU33 Critical Care and Critical Health Issues</b></p><p><b>SU34 GI, Obesity, Metabolic, and Other Nutrition Related Concepts</b></p><p><b>SU35 Pediatric, Neonatal, Pregnancy, and Lactation</b></p><p><b>Parenteral Nutrition Therapy</b></p><p><b>Abstract of Distinction</b></p><p>Shaurya Mehta, BS<sup>1</sup>; Chandrashekhara Manithody, PhD<sup>1</sup>; Arun Verma, MD<sup>1</sup>; Christine Denton<sup>1</sup>; Kento Kurashima, MD, PhD<sup>1</sup>; Jordyn Wray<sup>1</sup>; Ashlesha Bagwe, MD<sup>1</sup>; Sree Kolli<sup>1</sup>; Marzena Swiderska-Syn<sup>1</sup>; Miguel Guzman, MD<sup>1</sup>; Sherri Besmer, MD<sup>1</sup>; Sonali Jain, MD<sup>1</sup>; Matthew Mchale, MD<sup>1</sup>; John Long, DVM<sup>1</sup>; Chelsea Hutchinson, MD<sup>1</sup>; Aaron Ericsson, DVM, PhD<sup>2</sup>; Ajay Jain, MD, DNB, MHA<sup>1</sup></p><p><sup>1</sup>Saint Louis University, St. Louis, MO; <sup>2</sup>University of Missouri, Columbia, MO</p><p><b>Financial Support:</b> None Reported.</p><p><b>Background:</b> Total parenteral nutrition (TPN) provides lifesaving nutritional support intravenously, however, is associated with significant side effects. Given gut microbial alterations noted with TPN, we hypothesized transferring intestinal microbiota from healthy controls to those on TPN would restore gut-systemic signaling and mitigate injury.</p><p><b>Methods:</b> Using our novel ambulatory model (US Provisional Patent: US 63/136,165), 31 piglets were randomly allocated to enteral nutrition (EN), TPN only, TPN + antibiotics (TPN-A) or TPN + post pyloric intestinal microbiota transplant (TPN-IMT) for 14 days. Gut, liver, and serum samples were assessed though histology, biochemistry, and qPCR. Stool samples underwent 16s rRNA sequencing. PERMANOVA, Jaccard and Bray-Curtis metrics were performed.</p><p><b>Results:</b> Significant bilirubin elevation in TPN and TPN-A vs EN (p < 0.0001) was prevented with IMT. Serum cytokine profiles revealed significantly higher IFN-G, TNF-alpha, IL-beta, IL-8, in TPN (p = 0.009/0.001/0.043/0.011), with preservation upon IMT. Significant gut-atrophy by villous/crypt ratio in TPN (p < 0.0001) and TPN-A (p = 0.0001) vs EN was prevented by IMT (p = 0.426 vs EN). Microbiota profiles using Principal Coordinate Analysis (PCA) demonstrated significant overlap between IMT and EN, with the largest separation in TPN-A followed by TPN, driven primarily by firmicutes and fusobacteria. TPN altered gut barrier (Claudin-3 and Occludin) was preserved upon IMT. Gene expression showed upregulation of CYP7A1 and BSEP in TPN and TPN-A, with downregulation of FGFR4, EGF, FXR and TGR5 vs EN and prevention with IMT. In a subgroup analysis on TPN and EN, regional gut integrity differences were analyzed through the varying presence of E-cadherin and Occludin in the segment
{"title":"Nutrition and Metabolism Research Oral Paper Session Abstracts","authors":"","doi":"10.1002/jpen.2733","DOIUrl":"10.1002/jpen.2733","url":null,"abstract":"<p><b>Sunday, March 23, 2025</b></p><p><b>SU30 Parenteral Nutrition Therapy</b></p><p><b>SU31 Enteral Nutrition Therapy</b></p><p><b>SU32 Malnutrition and Nutrition Assessment</b></p><p><b>SU33 Critical Care and Critical Health Issues</b></p><p><b>SU34 GI, Obesity, Metabolic, and Other Nutrition Related Concepts</b></p><p><b>SU35 Pediatric, Neonatal, Pregnancy, and Lactation</b></p><p><b>Parenteral Nutrition Therapy</b></p><p><b>Abstract of Distinction</b></p><p>Shaurya Mehta, BS<sup>1</sup>; Chandrashekhara Manithody, PhD<sup>1</sup>; Arun Verma, MD<sup>1</sup>; Christine Denton<sup>1</sup>; Kento Kurashima, MD, PhD<sup>1</sup>; Jordyn Wray<sup>1</sup>; Ashlesha Bagwe, MD<sup>1</sup>; Sree Kolli<sup>1</sup>; Marzena Swiderska-Syn<sup>1</sup>; Miguel Guzman, MD<sup>1</sup>; Sherri Besmer, MD<sup>1</sup>; Sonali Jain, MD<sup>1</sup>; Matthew Mchale, MD<sup>1</sup>; John Long, DVM<sup>1</sup>; Chelsea Hutchinson, MD<sup>1</sup>; Aaron Ericsson, DVM, PhD<sup>2</sup>; Ajay Jain, MD, DNB, MHA<sup>1</sup></p><p><sup>1</sup>Saint Louis University, St. Louis, MO; <sup>2</sup>University of Missouri, Columbia, MO</p><p><b>Financial Support:</b> None Reported.</p><p><b>Background:</b> Total parenteral nutrition (TPN) provides lifesaving nutritional support intravenously, however, is associated with significant side effects. Given gut microbial alterations noted with TPN, we hypothesized transferring intestinal microbiota from healthy controls to those on TPN would restore gut-systemic signaling and mitigate injury.</p><p><b>Methods:</b> Using our novel ambulatory model (US Provisional Patent: US 63/136,165), 31 piglets were randomly allocated to enteral nutrition (EN), TPN only, TPN + antibiotics (TPN-A) or TPN + post pyloric intestinal microbiota transplant (TPN-IMT) for 14 days. Gut, liver, and serum samples were assessed though histology, biochemistry, and qPCR. Stool samples underwent 16s rRNA sequencing. PERMANOVA, Jaccard and Bray-Curtis metrics were performed.</p><p><b>Results:</b> Significant bilirubin elevation in TPN and TPN-A vs EN (p < 0.0001) was prevented with IMT. Serum cytokine profiles revealed significantly higher IFN-G, TNF-alpha, IL-beta, IL-8, in TPN (p = 0.009/0.001/0.043/0.011), with preservation upon IMT. Significant gut-atrophy by villous/crypt ratio in TPN (p < 0.0001) and TPN-A (p = 0.0001) vs EN was prevented by IMT (p = 0.426 vs EN). Microbiota profiles using Principal Coordinate Analysis (PCA) demonstrated significant overlap between IMT and EN, with the largest separation in TPN-A followed by TPN, driven primarily by firmicutes and fusobacteria. TPN altered gut barrier (Claudin-3 and Occludin) was preserved upon IMT. Gene expression showed upregulation of CYP7A1 and BSEP in TPN and TPN-A, with downregulation of FGFR4, EGF, FXR and TGR5 vs EN and prevention with IMT. In a subgroup analysis on TPN and EN, regional gut integrity differences were analyzed through the varying presence of E-cadherin and Occludin in the segment","PeriodicalId":16668,"journal":{"name":"Journal of Parenteral and Enteral Nutrition","volume":"49 S1","pages":"S5-S80"},"PeriodicalIF":4.1,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jpen.2733","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p><b>P1–P34 Parenteral Nutrition Therapy</b></p><p><b>P35–P52 Enteral Nutrition Therapy</b></p><p><b>P53–P83 Malnutrition and Nutrition Assessment</b></p><p><b>P84–P103 Critical Care and Critical Health Issues</b></p><p><b>P104–P131 GI, Obesity, Metabolic, and Other Nutrition Related Concepts</b></p><p><b>P132–P165 Pediatric, Neonatal, Pregnancy, and Lactation</b></p><p><b>Parenteral Nutrition Therapy</b></p><p>Sarah Williams, MD, CNSC<sup>1</sup>; Angela Zimmerman, RD, CNSC<sup>2</sup>; Denise Jezerski, RD, CNSC<sup>2</sup>; Ashley Bestgen, RD, CNSC<sup>2</sup></p><p><sup>1</sup>Cleveland Clinic Foundation, Parma, OH; <sup>2</sup>Cleveland Clinic Foundation, Cleveland, OH</p><p><b>Financial Support:</b> Morrison Healthcare.</p><p><b>Background:</b> Essential fatty acid deficiency (EFAD) is a rare disorder among the general population but can be a concern in patients reliant on home parenteral nutrition (HPN), particularly those who are not receiving intravenous lipid emulsions (ILE). In the US, the only ILE available until 2016 was soybean oil based (SO-ILE), which contains more than adequate amounts of essential fatty acids, including alpha-linolenic acid (ALA, an omega-3 fatty acid) and linoleic acid (LA, an omega-6 fatty acid). In 2016, a mixed ILE containing soybean oil, medium chain triglycerides, olive oil and fish oil, became available (SO, MCT, OO, FO-ILE). However, it contains a lower concentration of essential fatty acids compared to SO-ILE, raising theoretical concerns for development of EFAD if not administered in adequate amounts. Liver dysfunction is a common complication in HPN patients that can occur with soybean based ILE use due to their pro-inflammatory properties. Short-term studies and case reports in patients receiving SO, MCT, OO, FO-ILE have shown improvements in liver dysfunction for some patients. Our study evaluates the long-term impact of SO, MCT, OO, FO-ILE in our HPN patient population.</p><p><b>Methods:</b> This single-center, retrospective cohort study was conducted at the Cleveland Clinic Center for Human Nutrition using data from 2017 to 2020. It involved adult patients who received HPN with SO, MCT, OO, FO-ILE for a minimum of one year. The study assessed changes in essential fatty acid profiles, including triene-tetraene ratios (TTRs) and liver function tests (LFTs) over the year. Data was described as mean and standard deviation for normal distributed continuous variables, medians and interquartile range for non-normally distributed continuous variables and frequency for categorical variables. The Wilcoxon signed rank test was used to compare the baseline and follow-up TTR values (mixed time points). The Wilcoxon signed rank test with pairwise comparisons was used to compare the LFTs at different time points and to determine which time groups were different. P-values were adjusted using Bonferroni corrections. Ordinal logistic regression was used to assess the association between lipid dosing and follow-up T
{"title":"Poster Abstracts","authors":"","doi":"10.1002/jpen.2735","DOIUrl":"10.1002/jpen.2735","url":null,"abstract":"<p><b>P1–P34 Parenteral Nutrition Therapy</b></p><p><b>P35–P52 Enteral Nutrition Therapy</b></p><p><b>P53–P83 Malnutrition and Nutrition Assessment</b></p><p><b>P84–P103 Critical Care and Critical Health Issues</b></p><p><b>P104–P131 GI, Obesity, Metabolic, and Other Nutrition Related Concepts</b></p><p><b>P132–P165 Pediatric, Neonatal, Pregnancy, and Lactation</b></p><p><b>Parenteral Nutrition Therapy</b></p><p>Sarah Williams, MD, CNSC<sup>1</sup>; Angela Zimmerman, RD, CNSC<sup>2</sup>; Denise Jezerski, RD, CNSC<sup>2</sup>; Ashley Bestgen, RD, CNSC<sup>2</sup></p><p><sup>1</sup>Cleveland Clinic Foundation, Parma, OH; <sup>2</sup>Cleveland Clinic Foundation, Cleveland, OH</p><p><b>Financial Support:</b> Morrison Healthcare.</p><p><b>Background:</b> Essential fatty acid deficiency (EFAD) is a rare disorder among the general population but can be a concern in patients reliant on home parenteral nutrition (HPN), particularly those who are not receiving intravenous lipid emulsions (ILE). In the US, the only ILE available until 2016 was soybean oil based (SO-ILE), which contains more than adequate amounts of essential fatty acids, including alpha-linolenic acid (ALA, an omega-3 fatty acid) and linoleic acid (LA, an omega-6 fatty acid). In 2016, a mixed ILE containing soybean oil, medium chain triglycerides, olive oil and fish oil, became available (SO, MCT, OO, FO-ILE). However, it contains a lower concentration of essential fatty acids compared to SO-ILE, raising theoretical concerns for development of EFAD if not administered in adequate amounts. Liver dysfunction is a common complication in HPN patients that can occur with soybean based ILE use due to their pro-inflammatory properties. Short-term studies and case reports in patients receiving SO, MCT, OO, FO-ILE have shown improvements in liver dysfunction for some patients. Our study evaluates the long-term impact of SO, MCT, OO, FO-ILE in our HPN patient population.</p><p><b>Methods:</b> This single-center, retrospective cohort study was conducted at the Cleveland Clinic Center for Human Nutrition using data from 2017 to 2020. It involved adult patients who received HPN with SO, MCT, OO, FO-ILE for a minimum of one year. The study assessed changes in essential fatty acid profiles, including triene-tetraene ratios (TTRs) and liver function tests (LFTs) over the year. Data was described as mean and standard deviation for normal distributed continuous variables, medians and interquartile range for non-normally distributed continuous variables and frequency for categorical variables. The Wilcoxon signed rank test was used to compare the baseline and follow-up TTR values (mixed time points). The Wilcoxon signed rank test with pairwise comparisons was used to compare the LFTs at different time points and to determine which time groups were different. P-values were adjusted using Bonferroni corrections. Ordinal logistic regression was used to assess the association between lipid dosing and follow-up T","PeriodicalId":16668,"journal":{"name":"Journal of Parenteral and Enteral Nutrition","volume":"49 S1","pages":"S90-S308"},"PeriodicalIF":4.1,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jpen.2735","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p>The American Society for Parenteral and Enteral Nutrition (ASPEN) Abstract Review Committee reviews, ranks and selects scientific and clinical practice abstracts submitted for presentation at the annual ASPEN Nutrition Science & Practice Conference. Members of this committee are experts in the field and have the necessary skills to review and evaluate submitted research abstracts, many of which are eligible for several prestigious abstract awards. Committee members may also serve as moderators in the oral paper sessions at the ASPEN Nutrition Science & Practice Conference. In compliance with accreditation standards, committee members complete conflicts of interest statements prior to participation and industry representatives and employees are not appointed to this committee.</p><p><b>The 2024–2025 ASPEN Abstract Review Committee</b></p><p><i>Co-Chairs</i>: April Church and Paul McCarthy</p><p><i>Parenteral Nutrition Therapy Group Leader:</i> Mireille Hamdan</p><p><i>Enteral Nutrition Therapy Group Leader:</i> Joy Douglas</p><p><i>Malnutrition and Nutrition Assessment Group Leader:</i> Jana Ponce</p><p><i>Critical Care and Critical Health Issues Group Leader:</i> Caran Graves</p><p><i>GI, Obesity, Metabolic, and Other Nutrition Related Concepts Group Leader:</i> Lindsey Russell</p><p><i>Pediatric, Neonatal, Pregnancy, and Lactation Group Leader:</i> Laura Gearman</p><p><i>ASPEN Board liaison to the committee: Anne Tucker</i></p><p><i>At-Large Committee Members:</i></p><p>Andrew Adorno</p><p>Monica Agarwal</p><p>Christine Allen</p><p>Mohammad Alsharhan</p><p>Leah Anderson</p><p>Stephanie Bachi De Castro Oliveira</p><p>Sarita Bajpai</p><p>Janice Baker</p><p>Lauren Beckman</p><p>Jonathan Berken</p><p>Miss Zainab Bibi</p><p>Barbara Bielawska</p><p>Ellen Bowser</p><p>Rebecca Brody</p><p>Cassandra Brown</p><p>Christopher Buckley</p><p>Lingtak-Neander Chan</p><p>Lee-anne Chapple</p><p>Anisha Chhibber</p><p>Adeeti Chiplunker</p><p>Vikram Christian</p><p>Laura Cutten</p><p>Valentina Da Prat</p><p>Emily Diemer</p><p>Felecia Dispense</p><p>Angela DiTucci</p><p>Jithinraj Edakkanambeth Varayil</p><p>Arlene Escuro</p><p>Gustave Falciglia</p><p>Kristy Feeney</p><p>Megan Follett</p><p>Amanda Gilhool</p><p>Allison Gomes</p><p>Shanna Hager</p><p>Benjamin Hall</p><p>Maria Hetherton</p><p>Jessie Hulst</p><p>Carol Ireton-Jones</p><p>Muna Islami</p><p>Syed-Mohammed Jafri</p><p>Renuka Jayatissa</p><p>Lisa Kinder</p><p>Merin Kinikini</p><p>Mark Klang</p><p>Samuel Kocoshis</p><p>Gabriela Lemos</p><p>Ada Lin</p><p>Rachel Ludke</p><p>Kristen MacEachern</p><p>Diana Mager</p><p>Abigail Martin</p><p>Christine Meissner</p><p>Yolanda Del Carmen Mendez</p><p>Lauri Metzger</p><p>Osman Mohamed Elfadil</p><p>Dawna Mughal</p><p>Samantha Mumford</p><p>Kristin Munroe</p><p>Michele Nicolo</p><p>Aimuan Oreavbiere</p><p>Hannah Piper</p><p>Jessica Pollard</p><p>Emily Ryder</p><p>William San Pablo</p><p>Senthilkumar Sankararaman</p><p>Christine Scarcello</p><p>Parul Sharma</p><p
{"title":"2024–2025 ASPEN Abstract Review Committee","authors":"","doi":"10.1002/jpen.2736","DOIUrl":"10.1002/jpen.2736","url":null,"abstract":"<p>The American Society for Parenteral and Enteral Nutrition (ASPEN) Abstract Review Committee reviews, ranks and selects scientific and clinical practice abstracts submitted for presentation at the annual ASPEN Nutrition Science & Practice Conference. Members of this committee are experts in the field and have the necessary skills to review and evaluate submitted research abstracts, many of which are eligible for several prestigious abstract awards. Committee members may also serve as moderators in the oral paper sessions at the ASPEN Nutrition Science & Practice Conference. In compliance with accreditation standards, committee members complete conflicts of interest statements prior to participation and industry representatives and employees are not appointed to this committee.</p><p><b>The 2024–2025 ASPEN Abstract Review Committee</b></p><p><i>Co-Chairs</i>: April Church and Paul McCarthy</p><p><i>Parenteral Nutrition Therapy Group Leader:</i> Mireille Hamdan</p><p><i>Enteral Nutrition Therapy Group Leader:</i> Joy Douglas</p><p><i>Malnutrition and Nutrition Assessment Group Leader:</i> Jana Ponce</p><p><i>Critical Care and Critical Health Issues Group Leader:</i> Caran Graves</p><p><i>GI, Obesity, Metabolic, and Other Nutrition Related Concepts Group Leader:</i> Lindsey Russell</p><p><i>Pediatric, Neonatal, Pregnancy, and Lactation Group Leader:</i> Laura Gearman</p><p><i>ASPEN Board liaison to the committee: Anne Tucker</i></p><p><i>At-Large Committee Members:</i></p><p>Andrew Adorno</p><p>Monica Agarwal</p><p>Christine Allen</p><p>Mohammad Alsharhan</p><p>Leah Anderson</p><p>Stephanie Bachi De Castro Oliveira</p><p>Sarita Bajpai</p><p>Janice Baker</p><p>Lauren Beckman</p><p>Jonathan Berken</p><p>Miss Zainab Bibi</p><p>Barbara Bielawska</p><p>Ellen Bowser</p><p>Rebecca Brody</p><p>Cassandra Brown</p><p>Christopher Buckley</p><p>Lingtak-Neander Chan</p><p>Lee-anne Chapple</p><p>Anisha Chhibber</p><p>Adeeti Chiplunker</p><p>Vikram Christian</p><p>Laura Cutten</p><p>Valentina Da Prat</p><p>Emily Diemer</p><p>Felecia Dispense</p><p>Angela DiTucci</p><p>Jithinraj Edakkanambeth Varayil</p><p>Arlene Escuro</p><p>Gustave Falciglia</p><p>Kristy Feeney</p><p>Megan Follett</p><p>Amanda Gilhool</p><p>Allison Gomes</p><p>Shanna Hager</p><p>Benjamin Hall</p><p>Maria Hetherton</p><p>Jessie Hulst</p><p>Carol Ireton-Jones</p><p>Muna Islami</p><p>Syed-Mohammed Jafri</p><p>Renuka Jayatissa</p><p>Lisa Kinder</p><p>Merin Kinikini</p><p>Mark Klang</p><p>Samuel Kocoshis</p><p>Gabriela Lemos</p><p>Ada Lin</p><p>Rachel Ludke</p><p>Kristen MacEachern</p><p>Diana Mager</p><p>Abigail Martin</p><p>Christine Meissner</p><p>Yolanda Del Carmen Mendez</p><p>Lauri Metzger</p><p>Osman Mohamed Elfadil</p><p>Dawna Mughal</p><p>Samantha Mumford</p><p>Kristin Munroe</p><p>Michele Nicolo</p><p>Aimuan Oreavbiere</p><p>Hannah Piper</p><p>Jessica Pollard</p><p>Emily Ryder</p><p>William San Pablo</p><p>Senthilkumar Sankararaman</p><p>Christine Scarcello</p><p>Parul Sharma</p><p","PeriodicalId":16668,"journal":{"name":"Journal of Parenteral and Enteral Nutrition","volume":"49 S1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jpen.2736","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143689050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p>Monday, March 24, 2025</p><p>Premier Paper Session and Vars Award Competition</p><p><b>Harry M. Vars Award Candidate</b></p><p>Lizl Veldsman, RD, M Nutr, BSc Dietetics<sup>1</sup>; Guy Richards, MD, PhD<sup>2</sup>; Daniel Nel, PhD<sup>3</sup>; Renée Blaauw, PhD, RD<sup>1</sup></p><p><sup>1</sup>Division of Human Nutrition, Department of Global Health, Faculty of Medicine & Health Sciences, Stellenbosch University, Cape Town, Western Cape; <sup>2</sup>Department of Surgery, Division of Critical Care, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng; <sup>3</sup>Centre for Statistical Consultation, Department of Statistics and Actuarial Science, Stellenbosch University, Stellenbosch, Western Cape</p><p><b>Financial Support:</b> This research study was funded by the Fresenius Kabi Jumpstart Research grant.</p><p><b>Background:</b> Critical illness is associated with severe muscle wasting. A combination of protein supplementation and mobilization may attenuate muscle loss. We determined the effect of a combination of intravenous (IV) bolus amino acid (AA) supplementation and in-bed cycling, versus standard care only, on skeletal muscle mass during the first ICU week.</p><p><b>Methods:</b> This randomized controlled trial (ClinicalTrials.gov NCT04099108) was undertaken in a predominantly trauma adult surgical ICU. Participants were randomly assigned into two groups, both of which received standard care nutrition (SCN) and mobilization. The intervention group received an additional IV AA bolus, starting on ICU day 3 on-average, along with a 45-minute in-bed cycling session for a mean of 6 days. Histological change in vastus lateralis (VL) myofiber cross-sectional area (CSA) and ultrasound rectus femoris (RF) muscle CSA was measured from pre-intervention (average ICU day 2) to post-intervention (average ICU day 8) and analyzed using mixed model ANOVA and post hoc least significant difference (LSD) testing. Secondarily, we assessed the change in the protein-to-DNA ratio over time. We further compared responses between participants with and without baseline organ dysfunction (defined as SOFA≥2, due to infection or trauma-related inflammation).</p><p><b>Results:</b> Fifty critically ill patients (90% male, mean age 37±12 years, APACHE II score 13.5±6.6, SOFA score 4.5±3.2, BMI 24.8±4.0 kg/m<sup>2</sup>, modified NUTRIC 2.2±1.8) were included. The control (n = 25) and intervention (n = 25) groups received, on average, 87.62±32.18 and 85.53±29.29 grams of protein per day (1.26±0.41 and 1.29±0.40g/kg/day, respectively) from SCN, and the intervention group an additional 30.43±5.62 grams of AA (0.37±0.06g/kg protein equivalents) from the supplement. There was significant loss of muscle mass over time in all participants (VL myofiber CSA 11.76%, p = 0.011; RF muscle CSA 13.01% p < 0.001). No significant difference was found between groups, but a more compatible trend for greater muscle loss in the control group versus
2025年3月24日,星期一,主要论文会议和Vars奖竞赛harry M. Vars奖候选人elizl Veldsman, RD, M nur, BSc dietetic1;Guy Richards, MD, PhD2;Daniel Nel博士;ren<s:1> e Blaauw,博士,医学学院全球健康系人类营养研究室;西开普省开普敦斯泰伦博斯大学健康科学系;2约翰内斯堡,豪登省威特沃特斯兰德大学健康科学学院重症监护科外科;3 Stellenbosch大学统计与精算科学系统计咨询中心,Stellenbosch,西开普省Stellenbosch。财政支持:本研究由Fresenius Kabi Jumpstart research基金资助。背景:危重症与严重的肌肉萎缩有关。补充蛋白质和运动相结合可以减轻肌肉损失。我们确定了静脉注射(IV)氨基酸(AA)补充和床上循环相结合,与标准护理相比,在ICU第一周对骨骼肌质量的影响。方法:该随机对照试验(ClinicalTrials.gov NCT04099108)在主要为创伤的成人外科ICU进行。参与者被随机分为两组,两组均接受标准护理营养(SCN)和动员。干预组平均在ICU第3天开始接受额外的静脉注射AA,同时进行45分钟的床上骑行,平均持续6天。从干预前(平均ICU第2天)到干预后(平均ICU第8天)测量股外侧肌(VL)肌纤维横截面积(CSA)和超声股直肌(RF)肌肉CSA的组织学变化,并采用混合模型方差分析和事后最小显著性差异(LSD)检验进行分析。其次,我们评估了蛋白质与dna比率随时间的变化。我们进一步比较了有和没有基线器官功能障碍(定义为SOFA≥2,由于感染或创伤相关炎症)的参与者之间的反应。结果:纳入危重患者50例(男性90%,平均年龄37±12岁,APACHEⅱ评分13.5±6.6,SOFA评分4.5±3.2,BMI 24.8±4.0 kg/m2,改良NUTRIC评分2.2±1.8)。对照组(n = 25)和干预组(n = 25)平均每天从SCN中获得87.62±32.18和85.53±29.29 g蛋白质(分别为1.26±0.41和1.29±0.40g/kg/d),干预组从补充物中额外获得30.43±5.62 g AA(0.37±0.06g/kg蛋白质当量)。随着时间的推移,所有参与者的肌肉质量都显著下降(VL肌纤维CSA 11.76%, p = 0.011;RF肌CSA 13.01% p < 0.001)。两组间无显著差异,但对照组与干预组相比有更大的肌肉损失趋势(p = 0.051 vs p = 0.067)(表1)。随着时间的推移,蛋白质与dna比率显著上升(p = 0.007),但仅在干预组显著(对照组11.33%,p = 0.177;干预20.96%,p = 0.007)(表1)。调整基线器官功能障碍的混合模型方差分析显示研究组效应显著(p = 0.012)。事后LSD比较显示,在没有基线器官功能障碍的参与者中,对照组的VL肌纤维CSA损失明显更大(前:3803.19 vs后:2845.60,p = 0.034),而干预组未观察到显著损失(前:4580.19 vs后:4393.86,p = 0.787)。结论:患者在ICU的第一周出现明显的肌肉量损失。虽然对照组和干预组之间没有显著差异,但干预组的蛋白质与dna比率显著增加,表明对肌肉蛋白质含量有潜在的益处。此外,我们的研究结果表明,在没有基线器官功能障碍的患者中,干预可能更有效。未来的研究应将干预延长至第一个ICU周之后,以评估更长的干预时间是否能改善肌肉CSA并增强肌肉保存。表1。干预前后股外侧肌纤维横截面积(CSA)、股直肌CSA和蛋白- dna比值的变化。哈利·瓦尔斯奖候选人加布里埃拉·德·奥利维拉·莱莫斯,MD1;娜塔莎·门东帕拉·马查多博士;Raquel Torrinhas博士;Dan Linetzky Waitzberg,博士31圣保罗大学医学院,Brasília,联邦区;2巴西圣保罗大学医学院,巴西圣保罗;3巴西<s:1>圣保罗大学医学院,巴西圣保罗<e:1>财政支持:本研究与项目编号:2011/09612-3,由<s:1>圣保罗州研究支持基金会(FAPESP)资助。背景:鞘脂(Sphingolipids, SLs)有助于真核生物细胞膜的结构完整性,并在细胞调控的信号通路中发挥中介作用。 脂质分子(包括SLs)的积累可导致脂肪毒性、代谢失调、胰岛素抵抗和代谢疾病。本研究旨在评估肥胖和2型糖尿病(T2DM)女性患者Roux-en-Y胃旁路手术(RYGB)后血浆SLs与葡萄糖和胆固醇代谢生化指标以及体成分之间的关系。该调查是SURMetaGIT研究的一部分,注册于www.clinicalTrials.gov (NCT01251016)。方法:30例II-III级肥胖和2型糖尿病患者接受RYGB治疗。在基线和术后3个月进行评估。胰岛素治疗患者排除在外。对血浆样本进行生化(n=30)和代谢组学(n=28)分析。评估体重(kg)、身体成分(空气置换体积脉搏图)和人体测量指标。通过液相色谱-质谱联用的非靶向代谢组学分析鉴定了SLs。使用AnalysisBaseFileConverter和MS-DIAL进行数据处理和分析。采用Jamovi软件(2.2.5)和MetaboAnalyst 5.0进行统计。通过术后平均值/术前平均值的log2计算Fold change。组间比较采用配对t检验,采用正态性检验。相关性分析采用Spearman检验。α误差<; 0.05认为结果显著。结果:RYGB治疗后,患者体重、BMI、腰围、臀围均明显降低(图1)。患者在糖代谢方面有代谢改善:空腹血糖(215.8±72.4 vs 104±21.7 mg/dL),胰岛素(21.6±14.7 vs 11.1±9.2),糖化血红蛋白(8.9±1.6 vs 6.04±0.5),c肽(4.02±1.3 vs 2.9±0.8)- p< .001)。总胆固醇降低(192±30.7 vs 149.5±29.2 mg/dL, p = 0.004),以导致动脉粥样硬化的部分为代价:非hdl -c(143±35.5 vs 107±42 mg/dL, p = 0.001), LDL-c(114±29.5 vs 88.5±30.2 mg/dL, p = 0.01), VLDL-c(29.5±15 vs 21±7 mg/dL, p = 0.002), TG(150±85.2 vs 104.5±36.7 mg/dL, p = 0.004)。图2显示了RYGB前后SLs的热图。在34个确定的SLs中,有21个在手术后发生了显著变化(图3)。Cer (d18:1/23:0)和Cer (d42:1)与人体测量值和体脂呈中度负相关,但与瘦质量呈正相关。另一方面,SM (d38:2)表现出相反的效果。葡萄糖代谢生化指标与SLs之间的相关性较差,然而,这些变量与胆固醇及其组分之间表现出强烈而稳健的相关性,特别是在RYGB之后(表1)。结论:与RYGB
{"title":"Harry M. Vars Award Candidate Abstracts","authors":"","doi":"10.1002/jpen.2734","DOIUrl":"10.1002/jpen.2734","url":null,"abstract":"<p>Monday, March 24, 2025</p><p>Premier Paper Session and Vars Award Competition</p><p><b>Harry M. Vars Award Candidate</b></p><p>Lizl Veldsman, RD, M Nutr, BSc Dietetics<sup>1</sup>; Guy Richards, MD, PhD<sup>2</sup>; Daniel Nel, PhD<sup>3</sup>; Renée Blaauw, PhD, RD<sup>1</sup></p><p><sup>1</sup>Division of Human Nutrition, Department of Global Health, Faculty of Medicine & Health Sciences, Stellenbosch University, Cape Town, Western Cape; <sup>2</sup>Department of Surgery, Division of Critical Care, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng; <sup>3</sup>Centre for Statistical Consultation, Department of Statistics and Actuarial Science, Stellenbosch University, Stellenbosch, Western Cape</p><p><b>Financial Support:</b> This research study was funded by the Fresenius Kabi Jumpstart Research grant.</p><p><b>Background:</b> Critical illness is associated with severe muscle wasting. A combination of protein supplementation and mobilization may attenuate muscle loss. We determined the effect of a combination of intravenous (IV) bolus amino acid (AA) supplementation and in-bed cycling, versus standard care only, on skeletal muscle mass during the first ICU week.</p><p><b>Methods:</b> This randomized controlled trial (ClinicalTrials.gov NCT04099108) was undertaken in a predominantly trauma adult surgical ICU. Participants were randomly assigned into two groups, both of which received standard care nutrition (SCN) and mobilization. The intervention group received an additional IV AA bolus, starting on ICU day 3 on-average, along with a 45-minute in-bed cycling session for a mean of 6 days. Histological change in vastus lateralis (VL) myofiber cross-sectional area (CSA) and ultrasound rectus femoris (RF) muscle CSA was measured from pre-intervention (average ICU day 2) to post-intervention (average ICU day 8) and analyzed using mixed model ANOVA and post hoc least significant difference (LSD) testing. Secondarily, we assessed the change in the protein-to-DNA ratio over time. We further compared responses between participants with and without baseline organ dysfunction (defined as SOFA≥2, due to infection or trauma-related inflammation).</p><p><b>Results:</b> Fifty critically ill patients (90% male, mean age 37±12 years, APACHE II score 13.5±6.6, SOFA score 4.5±3.2, BMI 24.8±4.0 kg/m<sup>2</sup>, modified NUTRIC 2.2±1.8) were included. The control (n = 25) and intervention (n = 25) groups received, on average, 87.62±32.18 and 85.53±29.29 grams of protein per day (1.26±0.41 and 1.29±0.40g/kg/day, respectively) from SCN, and the intervention group an additional 30.43±5.62 grams of AA (0.37±0.06g/kg protein equivalents) from the supplement. There was significant loss of muscle mass over time in all participants (VL myofiber CSA 11.76%, p = 0.011; RF muscle CSA 13.01% p < 0.001). No significant difference was found between groups, but a more compatible trend for greater muscle loss in the control group versus","PeriodicalId":16668,"journal":{"name":"Journal of Parenteral and Enteral Nutrition","volume":"49 S1","pages":"S81-S89"},"PeriodicalIF":4.1,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jpen.2734","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The American Society for Parenteral and Enteral Nutrition (ASPEN) is dedicated to improving patient care by advancing the science and practice of clinical nutrition and metabolism. Founded in 1975, ASPEN is an interprofessional organization whose members are involved in the provision of clinical nutrition therapies, including parenteral and enteral nutrition. With more than 6000 members from around the world, ASPEN is a community of dietitians, nurses, pharmacists, physicians, scientists, students, and other health professionals from every facet of nutrition support clinical practice, research, and education.
ASPEN hosts an annual forum for clinical nutrition research and education, the ASPEN Nutrition Science & Practice Conference. The ASPEN Abstract Review Committee reviewed all abstracts submitted for the conference and selected those published herein for presentation. Selected abstracts feature data relevant to nutrition therapy and metabolic support, many of which were eligible for several of ASPEN's prestigious abstract awards.
The abstracts in this supplement have not been copyedited. Any errors contained within the abstracts are the sole responsibility of the authors. ASPEN does not assume liability for any errors herein. This content does not constitute medical or other professional advice. Please visit ASPEN's conference webpage for more information: https://www.nutritioncare.org/conference/
{"title":"Introduction to Conference Abstracts","authors":"","doi":"10.1002/jpen.2731","DOIUrl":"10.1002/jpen.2731","url":null,"abstract":"<p>The American Society for Parenteral and Enteral Nutrition (ASPEN) is dedicated to improving patient care by advancing the science and practice of clinical nutrition and metabolism. Founded in 1975, ASPEN is an interprofessional organization whose members are involved in the provision of clinical nutrition therapies, including parenteral and enteral nutrition. With more than 6000 members from around the world, ASPEN is a community of dietitians, nurses, pharmacists, physicians, scientists, students, and other health professionals from every facet of nutrition support clinical practice, research, and education.</p><p>ASPEN hosts an annual forum for clinical nutrition research and education, the ASPEN Nutrition Science & Practice Conference. The ASPEN Abstract Review Committee reviewed all abstracts submitted for the conference and selected those published herein for presentation. Selected abstracts feature data relevant to nutrition therapy and metabolic support, many of which were eligible for several of ASPEN's prestigious abstract awards.</p><p>The abstracts in this supplement have not been copyedited. Any errors contained within the abstracts are the sole responsibility of the authors. ASPEN does not assume liability for any errors herein. This content does not constitute medical or other professional advice. Please visit ASPEN's conference webpage for more information: https://www.nutritioncare.org/conference/</p>","PeriodicalId":16668,"journal":{"name":"Journal of Parenteral and Enteral Nutrition","volume":"49 S1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jpen.2731","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}